IRIS
TROIANO, Maria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 33.930
AS - Asia 10.553
EU - Europa 10.407
SA - Sud America 3.037
Continente sconosciuto - Info sul continente non disponibili 1.622
AF - Africa 569
OC - Oceania 28
Totale 60.146
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 33.134
SG - Singapore 4.242
IT - Italia 3.077
CN - Cina 2.428
BR - Brasile 2.343
RU - Federazione Russa 2.333
HK - Hong Kong 1.303
SE - Svezia 1.202
DE - Germania 719
VN - Vietnam 701
FR - Francia 641
FI - Finlandia 613
GB - Regno Unito 610
UA - Ucraina 500
BD - Bangladesh 342
IN - India 339
CA - Canada 338
AR - Argentina 248
CI - Costa d'Avorio 203
IQ - Iraq 155
ID - Indonesia 143
JP - Giappone 125
TR - Turchia 122
EC - Ecuador 118
MX - Messico 118
NL - Olanda 114
CO - Colombia 113
ZA - Sudafrica 109
PK - Pakistan 99
LT - Lituania 95
SA - Arabia Saudita 85
BE - Belgio 84
ES - Italia 84
VE - Venezuela 80
PL - Polonia 67
PH - Filippine 62
AT - Austria 61
CR - Costa Rica 57
IR - Iran 52
UZ - Uzbekistan 52
IE - Irlanda 51
TN - Tunisia 46
MA - Marocco 44
JM - Giamaica 42
CL - Cile 41
MY - Malesia 41
JO - Giordania 38
EG - Egitto 36
HN - Honduras 32
PY - Paraguay 32
SV - El Salvador 32
TT - Trinidad e Tobago 32
KE - Kenya 31
IL - Israele 29
NI - Nicaragua 29
EU - Europa 24
PE - Perù 24
GT - Guatemala 23
AU - Australia 22
OM - Oman 22
AE - Emirati Arabi Uniti 21
CW - ???statistics.table.value.countryCode.CW??? 21
PR - Porto Rico 20
CZ - Repubblica Ceca 19
ET - Etiopia 18
BO - Bolivia 17
GP - Guadalupe 17
KZ - Kazakistan 17
UY - Uruguay 17
NP - Nepal 16
DO - Repubblica Dominicana 15
LB - Libano 15
PA - Panama 15
PT - Portogallo 14
RO - Romania 14
AL - Albania 13
BG - Bulgaria 13
DZ - Algeria 13
AZ - Azerbaigian 12
GR - Grecia 12
PS - Palestinian Territory 12
SN - Senegal 12
KR - Corea 11
CH - Svizzera 10
EE - Estonia 10
AO - Angola 9
SC - Seychelles 9
TH - Thailandia 9
BB - Barbados 8
KG - Kirghizistan 8
BH - Bahrain 7
HU - Ungheria 7
MD - Moldavia 7
QA - Qatar 7
DK - Danimarca 6
GE - Georgia 6
NG - Nigeria 6
NZ - Nuova Zelanda 6
SY - Repubblica araba siriana 6
BY - Bielorussia 5
Totale 58.462
Salva come PNG Salva come JPEG
Città #
Fairfield 3.851
Ashburn 3.314
Woodbridge 2.755
Singapore 2.168
Houston 1.850
San Jose 1.823
Chandler 1.816
Seattle 1.533
Hong Kong 1.302
Cambridge 1.300
Wilmington 1.200
Jacksonville 1.165
Ann Arbor 1.141
Milan 1.121
Dallas 896
Nyköping 895
Council Bluffs 679
Beijing 644
Lawrence 448
New York 437
Roxbury 432
Lauterbourg 411
Los Angeles 398
Nanjing 381
Rome 348
Des Moines 302
Boardman 294
Santa Clara 260
Bari 245
Helsinki 243
Princeton 240
São Paulo 224
Abidjan 203
Columbus 203
Ho Chi Minh City 197
San Diego 178
Brooklyn 176
Buffalo 156
Inglewood 148
London 131
Hanoi 130
Chicago 126
Munich 124
Tokyo 114
Figino 93
Shenyang 93
Rio de Janeiro 92
Hebei 91
Nuremberg 90
Norwalk 88
North Bergen 86
Dong Ket 85
Nanchang 85
Frankfurt am Main 83
Moscow 81
Jakarta 80
Toronto 80
Brussels 77
Montreal 77
Dearborn 76
Atlanta 73
Jiaxing 72
Paris 71
Turin 69
Guangzhou 67
Tianjin 67
Orem 66
Vilnius 64
Baghdad 62
San Francisco 62
Phoenix 60
Washington 59
Falkenstein 58
Dhaka 54
Warsaw 51
Changsha 50
Johannesburg 50
Amsterdam 49
Belo Horizonte 48
Naples 47
Dublin 46
Quito 45
Denver 43
San José 42
Shanghai 41
Bologna 40
The Dalles 40
Miami 39
Jeddah 38
Tashkent 38
Pune 37
Stockholm 37
Brasília 36
Medellín 34
Salt Lake City 34
Chennai 33
Kingston 33
Curitiba 32
Marseille 32
Amman 31
Totale 39.309
Salva come PNG Salva come JPEG
Nome #
A case report of double filtration plasmapheresis in an acute episode of multiple sclerosis 820
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study 770
Sustained Efficacy, Safety and High Adherence Rate of Onabotulinum Toxin Type A in Chronic Migraine Patients: A Multicentric Prospective Real-Life Study 335
Defining the role of NG2-expressing cells in experimental models of multiple sclerosis. A biofunctional analysis of the neurovascular unit in wild type and NG2 null mice 277
Translational readthrough generates new astrocyte AQP4 isoforms that modulate supramolecular clustering, glial endfeet localization, and water transport 274
Combined microRNA and mRNA expression analysis in pediatric multiple sclerosis: an integrated approach to uncover novel pathogenic mechanisms of the disease. 266
The role of sexual dysfunction and attachment style in migraine related quality of life 266
Association between miRNAs expression and cognitive performances of Pediatric Multiple Sclerosis patients: A pilot study 261
Signs and symptoms of COVID-19 in patients with multiple sclerosis 249
Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study 242
A rare association of anti-alanine-transfer RNA synthetase (anti-PL12) syndrome and sporadic inclusion body myositis 242
A pattern of cognitive deficits stratified for genetic and environmental risk reliably classifies patients with schizophrenia from healthy control subjects 241
RELATIONSHIP OF COGNITIVE PERFORMANCES AND EMPLOYMENT STATUS IN PEOPLE WITH RELAPSING MULTIPLE SCLEROSIS 238
Association of Inflammation and Disability Accrual in Patients with Progressive-Onset Multiple Sclerosis 227
Correction to: Disability assessment using Google Maps (Neurological Sciences, (2022), 43, 2, (1007-1014), 10.1007/s10072-021-05389-7) 223
AQP4ex is crucial for the anchoring of AQP4 at the astrocyte end-feet and for neuromyelitis optica antibody binding 218
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis 215
The clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this? 210
DP71 and SERCA2 alteration in human neurons of a Duchenne muscular dystrophy patient 209
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis 204
Assessing response to interferon-β in a multicenter dataset of patients with MS 204
Autophagy markers LC3 and p62 accumulate in immune‐mediated necrotizing myopathy 201
Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS 200
Aquaporin-4 autoantibodies in Neuromyelitis Optica: AQP4 isoform-dependent sensitivity and specificity. 195
Sclerosi Multipla e Lavoro: dati preliminari 195
Prognostic indicators in pediatric clinically isolated syndrome 195
Age-related changes of serum N-acetyl-aspartate in healthy controls. 194
The Cost of Patients With Relapsing-Remitting Multiple Sclerosis Who Develop Neutralizing Antibodies While Treated With Interferon Beta 194
Gender differences in safety issues during Fingolimod therapy: Evidence from a real-life Relapsing Multiple Sclerosis cohort 193
Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis 193
A rare case of multiple sclerosis and McArdle disease 192
Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes 191
Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies 190
Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients 188
Adhesion molecules and matrix metalloproteinases in Multiple Sclerosis: effects induced by Interferon-beta 187
Comparative effectiveness of natalizumab and fingolimod treatment on cognitive functions in relapsing multiple sclerosis. ECTRIMS 2016 - Poster Session 2 187
A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year. 184
Host-Cell Type Dependent Features of Recombinant Human Aquaporin-4 Orthogonal Arrays of Particles-New Insights for Structural and Functional Studies 183
Analisi longitudinale dei livelli sierici di ICAM-1 solubile e dei subsets di linfociti T in pazienti con Sclerosi Multipla a decorso remittente in trattamento con IFNb-1b 182
Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register 180
Investigating the role of microRNA and transcription factor co-regulatory networks in multiple sclerosis pathogenesis 180
Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients 179
A systematic review of the incidence and prevalence of cancer in multiple sclerosis 179
A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview 177
Predictors of long-term disability accrual in relapse-onset multiple sclerosis 176
A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients 175
Age-related disability in multiple sclerosis 175
Lymphocyte count and body mass index as biomarkers of early treatment response in a multiple sclerosis dimethyl fumarate-treated cohort 174
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria 172
A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis 172
Cerebrospinal fluid neurofilament tracks fMRI correlates of attention at the first attack of Multiple Sclerosis 171
The Prevention of Post-Partum Relapses with Progestin and Estradiol in Multiple Sclerosis (POPART'MUS) trial: rationale, objectives and state of advancement 170
Computer-assisted rehabilitation of attention in patients with multiple sclerosis: results of a randomized, double-blind trial. 170
Risk of Guillain-Barré syndrome after 2010-2011 influenza vaccination. 169
The cognitive reserve theory in the setting of pediatric-onset multiple sclerosis 169
Development of an aquaporin-4 orthogonal array of particle-based ELISA for neuromyelitis optica autoantibodies detection 168
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. 168
The cost of relapsing-remitting multiple sclerosis patients who develop neutralizing antibodies during interferon beta therapy 167
Tissue distribution of the readthrough isoform of AQP4 reveals a dual role of AQP4ex limited to CNS 166
The brief international cognitive assessment for multiple sclerosis (BICAMS): Normative values with gender, age and education corrections in the Italian population 165
Perivascular and endomysial macrophages expressing VEGF and CXCL12 promote angiogenesis in anti-HMGCR immune-mediated necrotizing myopathy 165
Comparative efficacy of switching to natalizumab in active multiple sclerosis 164
Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis 164
SCLEROSI MULTIPLA E LAVORO: DATI PRELIMINARI 164
Defining reliable disability outcomes in multiple sclerosis 161
Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. 161
A sequence variation in the MOG gene is involved in multiple sclerosis susceptibility in Italy 160
Multiple sclerosis registries in Europe – An updated mapping survey 160
Glatiramer Acetate induces pro-apoptotic mechanisms involving Bcl-2, Bax and Cyt-c in peripheral lymphocytes from Multiple Sclerosis patients 158
Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study. 158
Cerebrospinal fluid neurofilament tracks fMRI correlates of attention at the first attack of multiple sclerosis. 156
Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment 156
Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study 156
The use of immunosuppressant therapy for multiple sclerosis in Italy: A multicenter retroprospective study 156
Illness Perception and Well-Being Among Persons with Multiple Sclerosis and Their Caregivers 156
Treatment decisions in multiple sclerosis-insights from real-world observational studies 156
The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: A systematic review 155
Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS 154
PBMC of Multiple Sclerosis Patients Show Deregulation of OPA1 Processing Associated with Increased ROS and PHB2 Protein Levels 154
Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis 153
Natalizumab discontinuation and disease restart in pregnancy: A case series 153
Load-dependent dysfunction of the putamen during attentional processing in patients with clinically isolated syndrome suggestive of multiple sclerosis. 153
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis 151
Multiple Sclerosis Progression and Relapse Activity in Children 150
BLOOD MMP-9 AND SICAM-1 AS MARKERS OF RIFN-B TREATMENT EFFICACY IN RELAPSING-REMITTING MS 150
Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study 150
Verbal fluency deficits in clinically isolated syndrome suggestive of multiple sclerosis. 149
Risk knowledge in relapsing multiple sclerosis (RIKNO 1.0) - Development of an outcome instrument for educational interventions 148
Aquaporin-4 Autoantibodies in Neuromyelitis Optica: AQP4 Isoform-Dependent Sensitivity and Specificity. 147
Epoch analysis of on-treatment disability progression events over time in the Tysabri Observational Program (TOP) 147
Caregiver quality of life in multiple sclerosis: a multicentre Italian study 146
Age-related vascular differences among patients suffering from multiple sclerosis 145
Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis 145
Association of Initial Disease-Modifying Therapy with Later Conversion to Secondary Progressive Multiple Sclerosis 145
Apolipoprotein E genotype does not influence the progression of multiple sclerosis 144
A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis 144
DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France 144
Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide 144
Defining secondary progressive multiple sclerosis 143
A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis 143
Totale 19.365
Salva come PNG Salva come JPEG
Categoria #
all - tutte 244.137
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 244.137
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.497 0 0 0 0 144 289 174 172 237 210 532 739
2022/20234.809 779 506 297 427 616 590 66 558 714 30 126 100
2023/20241.647 153 312 108 110 144 354 60 59 30 63 29 225
2024/20257.632 321 145 641 302 238 631 586 638 373 423 1.102 2.232
2025/202618.357 2.257 776 1.514 1.799 1.654 954 1.780 541 2.886 1.553 503 2.140
2026/20274.830 599 810 1.056 2.319 46 0 0 0 0 0 0 0
Totale 60.146